Cystic fibrosis and race

Cystic fibrosis (CF) is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. The disease is caused by mutations in the CFTR gene, which encodes a protein involved in the movement of chloride ions across epithelial cells, affecting the production of sweat, digestive fluids, and mucus.

Epidemiology

Cystic fibrosis is most common among individuals of European descent, with a prevalence of about 1 in 2,500 to 1 in 3,500 newborns in this demographic. The disease is less common in people of African descent, Asian descent, and Hispanic populations, with significantly lower incidence rates. The variation in prevalence among different races and ethnicities is primarily due to the distribution of CFTR gene mutations, which vary widely across populations.

Genetic Mutations and Race

The most common mutation causing cystic fibrosis, ΔF508, is found in approximately 70% of cases worldwide but is most prevalent among those of European ancestry. Other mutations may be more common in different racial or ethnic groups. For example, the 3120+1G→A mutation has a higher frequency in the Ashkenazi Jewish population, while the G551D mutation is found across various racial groups but with different frequencies.

Diagnosis and Screening

Newborn screening for cystic fibrosis is standard in many countries, allowing for early diagnosis and treatment. However, the effectiveness of these screening programs can vary among different racial and ethnic groups, partly due to the diversity of CFTR mutations. This diversity can lead to underdiagnosis or delayed diagnosis in populations where certain CFTR mutations are less well understood or not included in standard screening panels.

Treatment and Outcomes

Advancements in treatment have significantly improved the life expectancy and quality of life for individuals with cystic fibrosis. However, disparities in health outcomes exist among different racial and ethnic groups. Access to healthcare, socioeconomic status, and genetic factors contribute to these disparities. Studies have shown that individuals of non-European descent with cystic fibrosis may experience a more severe disease course and have lower life expectancies compared to their European counterparts.

Research and Future Directions

Ongoing research aims to better understand the genetic and environmental factors that contribute to the variability in cystic fibrosis symptoms and outcomes among different racial and ethnic groups. Efforts are also being made to develop treatments that are effective across the diverse range of CFTR mutations. Increasing the representation of minority populations in cystic fibrosis research is crucial for achieving these goals.

NIH genetic and rare disease info

• NIH info on Cystic fibrosis and race

Cystic fibrosis and race is a rare disease.

• 
  Protein CFTR PDB 1xmi
• 
  Cystic fibrosis manifestations
• 
  Bronchodilators
• 
  Elexacaftor tezacaftor ivacaftor mechanism of action